Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Tricaprilin Formulations in Healthy Males
NCT03971123Phase 1Completed
- Sponsor
- Cerecin
- Start
- Aug 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tricaprilin in Alzheimer's disease (AD) (5 arms), sponsored by Cerecin. Primary endpoints: Safety and Tolerability at 11 days, Area Under the Curve (AUC0-t) at 1 day and 2 more. Started Aug 2019; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03971123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03971123.